Cytoki Pharma Reports the First Patient Dosing with CK-0045 in the P-II Trial for Treating Obesity and Type 2 Diabetes
Shots:
- Cytoki Pharma has dosed the first patient with CK-0045 under the P-II clinical evaluation for treating obesity and type 2 diabetes
- The 16wk. P-II PoC trial will assess two doses of CK-0045 (SC, QW) in patients (n=90) with obesity & T2D to show metabolic benefits of IL-22 modulation such as weight loss, HbA1c, insulin sensitivity & lipid levels. Results are expected in H1’26
- CK-0045 is a long-acting analogue of IL-22 that is in-licensed from Novo Nordisk. Its P-I study results in healthy subjects verified target engagement, exposure-dependent reduced body mass, improved LDL cholesterol, insulin levels & insulin resistance, with a favorable safety profile
Ref: PR Newswire | Image: Cytoki Pharma
Related News:- Cytoki Pharma Reports Results from the P-I Study of CK-0045 to Improve Cardiometabolic Risk Factors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
